Evidence map›Paper›PMID 42484733›Full record

ArticleMedical oncology (Northwood, London, England)2026

A kinetically inert platinum antitumor agent overcomes mutant p53-driven chemoresistance via oxidative stress-mediated DNA damage.

Sourav Chakraborty, Priti S Shenoy, Sreyashi Nath, Tushar Ranjan Panda, Arpita Bhat, Asmita Sakpal, Megha Mehrotra, Prerna Singh, Malay Patra, Pritha Ray

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sourav ChakrabortyImaging Cell Signaling & Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, 410210, India.
Priti S ShenoyImaging Cell Signaling & Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, 410210, India.
Sreyashi NathImaging Cell Signaling & Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, 410210, India.
Tushar Ranjan PandaLaboratory of Medicinal Chemistry and Cell Biology, Department of Chemical Sciences, Tata Institute of Fundamental Research, Homi Bhabha Road, Navy Nagar, 400005, Mumbai, India.
Arpita BhatImaging Cell Signaling & Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, 410210, India.
Asmita SakpalImaging Cell Signaling & Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, 410210, India.
Megha MehrotraImaging Cell Signaling & Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, 410210, India.
Prerna SinghImaging Cell Signaling & Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, 410210, India.
Malay PatraLaboratory of Medicinal Chemistry and Cell Biology, Department of Chemical Sciences, Tata Institute of Fundamental Research, Homi Bhabha Road, Navy Nagar, 400005, Mumbai, India.
Pritha RayImaging Cell Signaling & Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, 410210, India. pray@actrec.gov.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapy resistance is a complex and multifaceted pathological phenomenon, often driven by mutations in the p53 tumor suppressor gene. This ultimately causes tumor recurrence thereby adversely affecting patient prognosis. Therefore, development of effective chemotherapeutic agents that simultaneously inhibit tumor proliferation and overcome resistance mechanisms is of paramount importance. Recently, we identified Compound 4, a kinetically inert platinum-based antitumor agent capable of bypassing platinum resistance while exhibiting minimal nephrotoxicity. However, its potency in resistance scenario is still not investigated. Herein we evaluate the efficacy of Compound 4 against platinum-resistant cancers driven by mutant p53, using engineered p53-null ovarian (SKOV3) and gastric (KATOIII) cancer cell lines expressing hot-spot p53 mutants (p53

Indexed as

Antineoplastic AgentsDNA DamageDrug Resistance, NeoplasmOxidative StressTumor Suppressor Protein p53Cell Line, TumorFemaleHumansMutationOvarian NeoplasmsAntineoplastic AgentsTP53 protein, humanTumor Suppressor Protein p53ChemoresistanceCisplatinDNA damageGastric cancerNovel anticancer agentOvarian cancerPlatinum analogue

Identifiers

PMID42484733

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.